OncLive TV

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the significance of molecular testing for patients with melanoma and when testing should occur.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses upcoming RESONATE-2 trial results for patients with chronic lymphocytic leukemia (CLL).

James Battiste, MD, PhD, assistant professor at the University of Oklahoma department of neurology and researcher at Stephenson Cancer Center, discusses research in glioblastoma (GBM).

Alec Koo, MD, FACS, managing partner, Skyline Urology, board of directors, LUGPA, discusses results from a recent study on active surveillance in prostate cancer.

Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses some of the challenges oncologists face with treating patients with pancreatic neuroendocrine tumors (pNETs).

Jason J. Luke, MD, FACP, assistant professor of medicine, Melanoma and Developmental Therapeutics Clinic, University of Chicago Medicine, discusses PD-1 inhibitors nivolumab and pembrolizumab as frontline immunotherapy choices for patients with melanoma.

Sanaz Memarzadeh, MD, associate professor of obstetrics and gynecology and the director of the Gynecologic Oncology (GO) discovery Lab at UCLA, discusses the benefits of hormonal therapy for endometrial tumors.

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses early efficacy signals in the phase I/II DART study.

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses optimizing neoadjuvant treatments for HER2-positive breast cancer.

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses immunotherapy in multiple myeloma and how it fits into the future treatment paradigm.

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the effects he has seen abiraterone have in patients with metastatic castration-resistant prostate cancer (mCRPC).

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses how treatment outcomes in melanoma have evolved over the last few years.

Kathy J. Schilling, MD, a radiologist at Boca Raton Regional Hospital, discusses the importance of additional screening for women with dense breasts.

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the risk factors of developing myelodysplastic syndromes (MDS) and any preventative measures.

Former NASA astronaut Tom Henricks will show how team dynamics and organizational culture affect outcomes using dramatic real-life video shot inside of a NASA space shuttle cockpit during launch and landing, as well as scenes of working in space, during a keynote address at the 8th Annual Interdisciplinary Prostate Cancer Congress (IPCC): and Other Genitourinary Malignancies.

Kathy Schilling, MD, radiologist, Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital, discusses screening methods for breast cancer.

Pamela L. Kunz, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses some anticipated trial results for patients with neuroendocrine and carcinoid tumors.

Randy Gascoyne, MD, hematopathologist and research director for the Centre for Lymphoid Cancers at the BC Cancer Agency in Canada, discusses a study that investigated biomarkers for follicular lymphoma.

Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University Medical Center, discusses VeriStrat testing for patients with non-small cell lung cancer.

Thomas Kipps, MD, PhD, Division of Hematology-Oncology Deputy Director for Research at the UC San Diego Moores Cancer Center, discusses the mechanisms of ibrutinib and idelalisib for the treatment of chronic lymphocytic leukemia (CLL).

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the challenges oncologists face with T-cell lymphoma.

Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Jim Feldman, chief innovative officer, Shift Happens, discusses change management for urologists and why it is important for them to have a social media presence.

Jonathan Henderson, MD, urologist, Regional Urology, assistant director of clinical research, discusses how men's health clinics should be run by urologists.

Dana Jacoby, senior consultant, BSM Consulting, gives advice on how a group of physicians can build a strong, healthy culture when looking to form a successful medical organization.

Bob Asinof, chief executive officer of The Urology Center of Colorado, discusses the challenges of recruiting urologists to their center while competing with larger cancer centers and hospital systems.

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.

Patrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses immunotherapy and how it can advance as a treatment option for patients with lung cancer.